# Study of Docetaxel in Breast Cancer Patients

> **NCT00174707** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 998 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile
- **DRUG:** epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile
- **DRUG:** epidoxorubicine, docetaxel, cyclophosphamide

## Key facts

- **NCT ID:** NCT00174707
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 998 (ACTUAL)
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00174707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00174707, "Study of Docetaxel in Breast Cancer Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00174707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*